title: Therapeutic modalities of exudative age-related macular degeneration.
abstract: BACKGROUND
  Age-related macular degeneration (AMD) is a leading cause of irreversible serious vision damage in persons over 50 years of age. In treating AMD many medicaments are applied such as inhibitors of vascular endothelial growth factor (VEGF), have been very carefully included over the last few years after a series of study research.
  
  
  OBJECTIVE
  To analyze the past methods of treatment, discuss emerging therapies which could advance the treatment of exudative AMD. The past anti-VEGF therapies require frequent repetitions of administration, with uncertain visual acuity recovery, as not all patients react to anti-VEGF therapy. Consequently, there is a need to find out additional therapies which could improve the treatment of exudative AMD. The real aim in the treating of AMD is to prevent CNV development.
  
  
  METHODS
  A survey of the current clinical research and results in the field of the present and future treatments of exudative AMD.
  
  
  RESULTS
  There are many areas of research into new methods of the exudative AMD treatment.
  
  
  CONCLUSIONS
  The future therapies for exudative AMD treatment have a potential not only to reduce the frequency of administration and follow-up visits, but also to improve effects of treatment by targeting additional ways of CNV development, increasing the aptitude of target binding and extending durability of treatment.
authors.forename: Milka
authors.initials: M
authors.lastname: Mavija
authors.forename: Emina
authors.initials: E
authors.lastname: Alimanovic
authors.forename: Vesna
authors.initials: V
authors.lastname: Jaksic
authors.forename: Sanja Sefic
authors.initials: SS
authors.lastname: Kasumovic
authors.forename: Sonja
authors.initials: S
authors.lastname: Cekic
authors.forename: Miroslav
authors.initials: M
authors.lastname: Stamenkovic
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use; D052157:Aptamers, Nucleotide / Q000627:therapeutic use; D000068258:Bevacizumab; D003131:Combined Modality Therapy; D006801:Humans; D007910:Lenses, Intraocular; D008268:Macular Degeneration / Q000628:therapy*; D011839:Radiation, Ionizing; D000069579:Ranibizumab; D040262:Receptors, Vascular Endothelial Growth Factor / Q000627:therapeutic use; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide; D011993:Recombinant Fusion Proteins; D042461:Vascular Endothelial Growth Factor A; C533178:aflibercept; C495058:pegaptanib; D000068258:Bevacizumab; D040262:Receptors, Vascular Endothelial Growth Factor; D000069579:Ranibizumab